RxDoctor Payments Data

Janet Wright, NP

Family · Dothan, ALNPI 1265942213

Payments from drug & device makers

$3,089in general payments, 2019–2025

Across 136 payments — averaging $22.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$2K
  • Merck$547
  • Gilead$443
  • Theratechnologies Inc.$260
  • Johnson & Johnson$227
  • EMD Serono, Inc.$16
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$3,04198%
  • Education$482%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,089 in reported general payments places this provider in the 80th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$1,182
Medicare patients
17
Services billed
26

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala348$1,461,734
JulucaDolutegravir/Rilpivirine154$558,302
DescovyEmtricitabine/Tenofov Alafenam243$522,709
TivicayDolutegravir Sodium224$513,738
PrezcobixDarunavir/Cobicistat116$283,808
TriumeqAbacavir/Dolutegravir/Lamivudi64$241,939
DovatoDolutegravir Sodium/Lamivudine52$150,088
Egrifta SvTesamorelin Acetate16$117,255
OdefseyEmtricitab/Rilpiviri/Tenof Ala30$111,318
GenvoyaElviteg/Cob/Emtri/Tenof Alafen27$104,771
CabenuvaCabotegravir/Rilpivirine13$91,380
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf13$55,371
CompleraEmtricita/Rilpivirine/Tenof Df12$42,609
IsentressRaltegravir Potassium13$29,848
Isentress HdRaltegravir Potassium13$22,830

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$443$2,089,213618 claims
Viiv Healthcare CompanyJuluca, Tivicay, Triumeq, Dovato, Cabenuva$1,580$1,555,448507 claims
Johnson & JohnsonPrezcobix, Complera$227$326,417128 claims
Theratechnologies Inc.Egrifta Sv$260$117,25516 claims
MerckIsentress, Isentress Hd, Janumet Xr$547$58,60637 claims
Janssen Products, LPSymtuza$16$55,37113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,415 family providers in Alabama.

Other family in Dothan

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →